Erik Sjögren, Assoc. Prof., Ph.D.

Principal Director, PBPK & PBBM Scientific Lead

Portrait-of-Erik-Sjogren_Pharmetheus-2

Bio

  • Joined Pharmetheus in 2017, actively working in client projects, serving as PBPK & PBBM Platform Scientific Lead
  • Expertise includes physiological based pharmacokinetic and biopharmaceutics modeling and simulation, clinical pharmacology, and pediatrics across therapeutic areas
  • Experience as Researcher at Uppsala University, Sweden, where he has a part-time position to perform research and supervise Ph.D. students. Previously, he worked as Acting Senior Lecturer at Uppsala University, Sweden and Postdoctoral Researcher at AstraZeneca Mölndal, Sweden
  • M.Sc. in Pharmaceutical Sciences (2004), Ph.D. in Pharmaceutical Sciences (2010), Associate Professor in Biopharmaceutics (2016) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Prediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) ModelingThe evolving role of in vitro – in vivo correlation in Model-Informed Drug Development: A multi-stakeholder perspectivePhysiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcomaHarnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community ConferenceAssessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic AbsorptionCurrent State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop ReportModel-informed drug development of a sustained release formulation of flucytosine in the treatment of cryptococcal meningitis: a case study using physiologically based pharmacokinetic modelingPhysiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case studyA quantitative systems pharmacology framework of immunogenicity to propose mitigation strategies after subcutaneous administrationOptimizing Formulations for Treatment of Cryptococcal Meningoencephalitis in Sub-Saharan HIV Patients: Insights from PBPK ModelingPBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space